Cover Image
市場調查報告書

院內感染治療藥的全球市場:2015年∼2019年

Global Hospital Infection Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 342625
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
院內感染治療藥的全球市場:2015年∼2019年 Global Hospital Infection Therapeutics Market 2015-2019
出版日期: 2015年10月21日 內容資訊: 英文 83 Pages
簡介

所謂院內感染,是在醫院和在其他醫療機關的疾病感染,院內感染有SSI、UTI、血液感染、肺炎球菌感染、MRSA、腸胃疾病等。院內感染現象可由嚴格遵守準則和減少對患者使用侵入性的設備。全球院內感染治療藥市場,2014年∼2019年期間中,預計年複合成長率成長3.24%。

本報告提供全球院內感染治療藥市場相關調查分析、產業概要、地區市場概要、推動市場的要素、市場課題、市場趨勢、主要供應商等相關彙整。

第1章 摘要整理

第2章 報告的範圍

第3章 市場調查的方法

  • 調查方法
  • 經濟指標

第4章 簡介

第5章 疾病概要

  • 理解疾病
  • 運輸方法
  • 感染的種類
  • 預防
  • 治療
  • 流行病學
  • 經濟負擔

第6章 開發平台分析

第7章 市場的狀況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:各藥物等級

  • 抗菌劑
  • 抗病毒藥物
  • 抗真菌劑

第9章 市場區隔:各感染種類

  • 尿道感染
  • 呼吸系統感染
  • 血液感染
  • 手術部位感染
  • 腸胃感染

第10章 各地區市場區隔

  • 全球院內感染治療藥市場:各地區

第11章 推動市場的要素

  • 多重抗藥性種的增加
  • 公共衛生相關關心的高漲
  • 特別指定開發平台分子
  • 手術數量的增加

第12章 促進要素的影響

  • 預防感染計劃的增加
  • 非專利的利用增加
  • 恰當的醫療基礎設施不足

第13章 市場課題

第14章 市場趨勢

第15章 供應商狀況

  • 競爭模式
  • 市場佔有率分析:2014年
  • 其他主要供應商

第16章 主要供應商分析

  • Allergan
  • Bayer HealthCare
  • GSK
  • Merck & Co
  • Pfizer

第17章 附錄

第18章 Technavio的其他報告

圖表

目錄
Product Code: IRTNTR7424

About hospital-acquired infections

Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient. Anti-infective drugs are used for the treatment of these infections. These infections can be minimized by following proper infection control measures in the hospitals and healthcare institutions.

Technavio's analysts forecast the global hospital infection therapeutics market to grow at a CAGR of 3.24% over the period 2014-2019.

Covered in this report

The report covers the present scenario and growth prospects of the global hospital infection therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the treatment of various hospital-acquired infections such as bloodstream infections, Clostridium difficile infections, hospital-acquired pneumonia, surgical site infections, and urinary tract infections.

Technavio's report, Global Hospital Infection Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital infection therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Allergan
  • Bayer
  • GlaxoSmithKline
  • Merck
  • Pfizer

Other Prominent Vendors

  • Abbott Laboratories
  • Achaogen
  • AmpliPhi Biosciences
  • Angelini Pharma
  • Aridis Pharmaceuticals
  • AstraZeneca
  • Durata Therapeutics
  • F. Hoffmann-La Roche
  • Isis Pharmaceuticals
  • Johnson & Johnson
  • Ligand Pharmaceuticals
  • Massachusetts Biological Laboratories
  • Medarex
  • Meiji Seika Pharma
  • Melinta Therapeutics
  • Nektar
  • Novartis
  • Prokarium
  • Sanofi
  • Tetraphase Pharmaceuticals
  • The Medicines Company
  • Valneva

Key market driver

  • Development of multidrug resistant variants
  • For a full, detailed list, view our report

Key market challenge

  • Rise in number of infection control programs
  • For a full, detailed list, view our report

Key market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding disease
  • Modes of transmission
  • Types of infections
  • Prevention
  • Treatment
  • Epidemiology
  • Economic burden

PART 06: Pipeline analysis

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by drug class

  • Antibacterials
  • Antiviral drugs
  • Antifungal drugs

PART 09: Market segmentation by type of infections

  • Urinary tract infections
  • Respiratory tract infections
  • Bloodstream infections
  • Surgical site infections
  • Gastrointestinal infections

PART 10: Geographical segmentation

  • Segmentation of global hospital infection therapeutics market by geography

PART 11: Market drivers

  • Development of multidrug resistant variants
  • Rise in public health awareness
  • Special regulatory designation for pipeline molecules
  • Increase in number of surgical procedures

PART 12: Impact of drivers

  • Rise in number of infection control programs
  • Increased use of generics
  • Lack of proper healthcare infrastructure

PART 13: Market challenges

PART 14: Market trends

PART 15: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 16: Key vendor analysis

  • Allergan
  • Bayer HealthCare
  • GSK
  • Merck & Co
  • Pfizer

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of contact transmission
  • Exhibit 03: Global hospital infection treatment market: Pipeline portfolio
  • Exhibit 04: Global hospital infection therapeutics market 2014-2019 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Global hospital infection therapeutics market segment by drug class
  • Exhibit 07: Types of antibacterial drug by chemical class
  • Exhibit 08: Types of antifungal drugs by chemical class
  • Exhibit 09: Global hospital infection therapeutics market segment by type of infections
  • Exhibit 10: Estimates of hospital-acquired infections occurring in acute care hospitals in the US 2011
  • Exhibit 11: Percentage share of market segment by type of infection 2014
  • Exhibit 12: Global hospital infection therapeutics market segment by geography 2014
  • Exhibit 13: Impact of drivers
  • Exhibit 14: Impact of drivers and challenges
  • Exhibit 15: Allergan: Key takeaways
  • Exhibit 16: Allergan: Year-over-year (YoY) growth and revenue generated from net sales of pharmaceutical products 2011-2014 ($ millions)
  • Exhibit 17: Allergan: YoY growth and revenue generated from net product sales of anti-infective 2011-2013 ($ millions)
  • Exhibit 18: Bayer: Key takeaways
  • Exhibit 19: GlaxoSmithKline: Key takeaways
  • Exhibit 20: GlaxoSmithKline: YoY growth and revenue generated from sales of Augmentin 2011-2014 ($ millions)
  • Exhibit 21: GlaxoSmithKline: Revenue generated from sales of Augmentin by region 2011-2014 ($ millions)
  • Exhibit 22: GlaxoSmithKline: YoY growth and revenue generated from sales of other antibacterial drugs 2013-2014 ($ millions)
  • Exhibit 23: Merck: Key takeaways
  • Exhibit 24: Merck: YoY growth and revenue generated from sales of Primaxin 2012-2014 ($ millions)
  • Exhibit 25: Merck: YoY growth and revenue generated from sales of Cancidas 2012-2014 ($ millions)
  • Exhibit 26: Merck: YoY growth and revenue generated from sales of Invanz 2012-2014 ($ millions)
  • Exhibit 27: Merck: YoY growth and revenue generated from sales of Noxafil 2012-2014 ($ millions)
  • Exhibit 28: Pfizer: Key takeaways
  • Exhibit 29: Pfizer: YoY growth and revenue generated from sales of Zyvox 2012-2014 ($ millions)
  • Exhibit 30: Pfizer: YoY growth and revenue generated from sales of Vfend 2012-2014 ($ millions)
  • Exhibit 31: Pfizer: YoY growth and revenue generated from sales of Zithromax and Zmax 2012-2014 ($ millions)
  • Exhibit 32: Pfizer: YoY growth and revenue generated from sales of Diflucan 2012-2014 ($ millions)
  • Exhibit 33: Pfizer: YoY growth and revenue generated from sales of Dalacin and Cleocin 2012-2014 ($ millions)
  • Exhibit 34: Allergan: Business segmentation 2014 by revenue
  • Exhibit 35: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 36: Allergan: Geographical segmentation by revenue 2014
  • Exhibit 37: Geographical segmentation by revenue 2014
  • Exhibit 38: Business segmentation by total revenue 2013 and 2014 ($ billions)
  • Exhibit 39: Pfizer in pharmaceutical sector
  • Exhibit 40: Geographical segmentation by revenue 2014
Back to Top